首页>
外国专利>
PROTEINACEOUS COMPOUND ACTIVATABLE BY BLOOD CLOTTING ENZYME TO HAVE FIBRINOLYTIC ACTIVITY OR INHIBIT CLOT FORMATION, SYNTHESIS, GENETIC ENGINEERING, DNA, VECTORS, HOST CELLS AND MEDICAMENTS
PROTEINACEOUS COMPOUND ACTIVATABLE BY BLOOD CLOTTING ENZYME TO HAVE FIBRINOLYTIC ACTIVITY OR INHIBIT CLOT FORMATION, SYNTHESIS, GENETIC ENGINEERING, DNA, VECTORS, HOST CELLS AND MEDICAMENTS
PCT No. PCT/GB90/01911 Sec. 371 Date Jun. 3, 1992 Sec. 102(e) Date Jun. 3, 1992 PCT Filed Dec. 7, 1990 PCT Pub. No. WO91/09125 PCT Pub. Date Jun. 27, 1991.Relatively inactive fusion proteins are activatable by enzymes of the clotting cascade to have fibrinolytic and/or clot formation inhibition activity. For example, a fusion protein comprising two hirudin or streptokinase molecules, linked by a cleavable linkage sequence, may be cleaved to yield anti-thrombotic hirudin or fibrinolytic streptokinase by thrombin or Factor Xa. Fibrinolytic or clot formation inhibition activity is therefore directed to the site of clot formation. Cleavable streptokinase/hirudin heterodimers are claimed.
展开▼